News

TB R&D Weekly Update: Results from First Novel Regimen Trial Published

23 Jul 2012
by Working Group
Announcements TB Drug Development TB News Video
EBA innovations new TB regimens phase II press publications r&d tb alliance treatment Video

Yesterday, efficacy data from the first novel regimen trial (NC001) were published in the Lancet. The results found that the regimen containing PA-824, moxifloxacin, and pyrazinamide, could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than existing treatments. Click here to read the full press release.

Tackling TB: Developing the First Novel Drug Regimen from TB Alliance on Vimeo.

Additional TB R&D News:

Absence of clinically relevant drug interaction between delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) and tenofovir or lopinavir/ritonavir in healthy subjects (IAC Abstract)

TB drugs chalk up rare win

Eradicate TB Through Public Awareness Campaigns: Educate The Public

Africa: Global Fund Results Show Broad Gains

More News
23 Aug 2022

PAN-TB Collaboration Announces Novel TB Drug Regimens Trial

The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...
4 May 2022

WHO Updates Treatment Guidance to Shorter, Novel Regimens for Drug-Resistant Tuberculosis

Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these...
5 Apr 2022

Online Consultation on Global Plan to End TB 2023-2030

On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May...